Fasturtec 1.5 mg (Rasburicase POWDER FOR SOLUTION) 1.5 MG

Fasturtec 1.5 mg is a powder for solution used for specific medical conditions. This intravenous medication is manufactured by Sanofi-Aventis Canada Inc.

Strength

1.5 MG

Pack Size

3VIALS

Manufacturer / TM Owner

SANOFI-AVENTIS CANADA INC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Fasturtec 1.5 mg is primarily used to manage elevated uric acid levels in the blood. This medication is often administered intravenously to help break down uric acid, which can be beneficial in certain medical conditions. Fasturtec is typically prescribed by healthcare professionals to address specific therapeutic needs related to uric acid management.

Side Effects

Fasturtec 1.5 mg may cause various effects, including changes in blood chemistry and potential allergic reactions. Some individuals might experience symptoms such as nausea, vomiting, or fever. It is important to monitor for any adverse reactions and consult a healthcare provider if concerns arise.

Precautions & Warnings

Fasturtec 1.5 mg should be handled with care, following the instructions provided by a healthcare professional. It is crucial to ensure proper storage and preparation of the solution to maintain its effectiveness. Patients should inform their healthcare provider about any existing medical conditions or allergies before starting treatment.

Avoid Interactions

Fasturtec 1.5 mg may interact with other medications, particularly those that affect blood chemistry or immune response. It is important to discuss all current medications with a healthcare provider to avoid potential interactions. Alcohol and certain foods might also influence the effectiveness of Fasturtec, so it is advisable to follow medical advice regarding lifestyle adjustments.

References

Frequently Asked Questions

Fasturtec 1.5 mg is used to manage elevated uric acid levels in the blood, often in specific medical conditions.

Fasturtec 1.5 mg is administered intravenously as a powder for solution.

Common side effects may include nausea, vomiting, fever, and changes in blood chemistry.

Potential interactions with other medications should be discussed with a healthcare provider to ensure safety.

Proper storage, preparation, and consultation with a healthcare provider are essential when using Fasturtec 1.5 mg.

Published by GNH India Pharmaceuticals Limited

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.